News

As part of the agreement, SCT and NexGen will license their respective technologies to ReNeu under world-wide, royalty-free licenses for the use of NexGen’s FDA-cleared EViTAR line of

The test will be made available to physician clients of Quest Diagnostics in certain regions in the US in March and available nationwide from April 2013. Panorama is

Under the licenses, Cedars-Sinai Medical Center can use Neuralstem’s intellectual property surrounding of spinal cord delivery platform, floating cannula, and method for delivering therapeutic agents. Cedars-Sinai Medical Center

On completion of acquisition, the facility, previously owned by KRU Medical, will continue to offer dialysis care and upscale amenities to patients in the New Smyrna Beach area.

Rare disease CDGP, if not treated, in adolescent boys may fail to reach full genetic height potential, experience adverse effects on skeletal proportions and bone mass, and delayed

The approval was based on the positive results of a 12-week multicenter, randomized, vehicle-controlled, double-blind pediatric study, which enrolled 285 acne sufferers aged 9 to 11 years. The

Eylea, which is formulated as an iso-osmotic solution for intravitreal administration, is designed for the treatment of diabetic macular edema (DME) in Russia, China, and other Asian countries.

NX-1207 is in late stage Phase 3 development in the US for the treatment of benign prostatic hyperplasia (BPH), a common condition of older men associated with growth

The study was conducted for a biotech sponsor developing a non-opioid analgesic. Spaulding Clinical Research general manager and senior vice president Daniel Selness said subject safety is the